A new biotech from a longtime developer wants to bring the targeted cancer revolution to the kids left behind
Daphne Haas-Kogan was treating and studying children’s brain tumors at the University of California San-Francisco, when she got a call that shook her. The pharma company whose drug she had been prepping for a trial had decided, despite all preclinical evidence, to not run any trials on kids, only adults. Haas-Kogan’s patients would not get the therapy.
“Ultimately the company had to make a decision for what trials they would support,” Haas-Kogan said. “I can still recall my blood pressure rising as I found out.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.